FARMINGDALE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. ('DepYmed” or the 'Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many poorly treated diseases that may benefit significantly by targeting the protein tyrosine phosphatase (PTP) family of enzymes. Today, DepYmed announces co-founder and research advisor Nicholas Tonks, Ph.D. will present data at the 9th World Rett Syndrome Congress in Queensland, Australia being held October 2-5, 2024.
Dr. Tonks' presentation, titled, 'PTP1B inhibition - a clinic-ready, mechanism-based approach to the treatment of Rett syndrome” will occur on October 3, 2024 at 4:30PM local time. In the presentation, Dr. Tonks discusses the nature of Rett syndrome as an X-linked neurological disorder caused primarily by mutations in a transcriptional regulator, methyl CpG binding protein 2 (MECP2). He then outlines the preclinical work completed for the Company's PTP1B inhibitor, DPM-1003, which improved a wide range of Rett syndrome phenotypes in RTT mice. He concludes that these data provide validation of PTP1B as a mechanism-based, therapeutic target for Rett syndrome, suggesting DPM-1003 as a new approach to therapeutic intervention in the disease. DPM-1003 is currently poised to enter clinical development and has been cleared by the FDA for clinical testing in the United States under an IND. At this time, the Company is actively raising funds to support this clinical initiative.